PMID- 32888896
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
VI  - 15
IP  - 2
DP  - 2021 Apr
TI  - Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 
      inhibitors regarding cardiovascular safety and mortality in type 2 diabetes 
      mellitus: A network meta-analysis.
PG  - 227-233
LID - S1751-9918(20)30248-5 [pii]
LID - 10.1016/j.pcd.2020.08.012 [doi]
AB  - AIM: The effects of dipeptidyl peptide-4 inhibitors (DPP-4is) and sodium-glucose 
      cotransporter-2 inhibitors (SGLT-2is) on type 2 diabetes mellitus (T2DM) on 
      cardiovascular events and all-cause mortality were compared. METHODS: The 
      literature on DPP-4is and SGLT-2is treatment of T2DM was searched through Pubmed, 
      Embase, and the web of science databases with the search deadline May 15, 2020. 
      Network meta-analysis (NMA) was used to compare the effects of two types of 
      inhibitors on cardiovascular events (major adverse cardiovascular events (MACE), 
      nonfatal myocardial infarction (MI), nonfatal stroke, and cardiovascular (CV) 
      death) and all-cause mortality in T2DM patients. RESULTS: A total of 15 articles 
      were screened, including 125,796 patients. Compared with DPP-4is, SGLT-2is can 
      significantly reduce MACE [OR: 0.86 95% CI (0.78, 0.92)], CV death [OR: 0.85 95% 
      CI (0.71, 1.01)], nonfatal MI [OR: 0.84 95%CI (0.74, 0.95)] and all-cause 
      mortality [OR: 0.78 95% CI (0.69, 0.89)]. For nonfatal stroke, DPP-4is and 
      SGLT-2is have no statistically significant difference [OR: 0.99 95% CI (0.91, 
      1.07)]. CONCLUSION: These data indicate that SGLT-2is is more beneficial to MACE 
      and all-cause mortality in T2DM patients than DPP-4is.
CI  - Copyright (c) 2020 Primary Care Diabetes Europe. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Hu, Jing
AU  - Hu J
AD  - Deptarment of Pharmacy, Shanghai Ruijin Rehabilitation Hospital, Shanghai 200023, 
      China. Electronic address: jinghu0202@163.com.
FAU - Chen, Liyun
AU  - Chen L
AD  - Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese 
      Medicine, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20200901
PL  - England
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Peptides)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
EIN - Prim Care Diabetes. 2021 Jun;15(3):623. PMID: 33839056
MH  - *Cardiovascular Diseases/diagnosis/prevention & control
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy
MH  - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Network Meta-Analysis
MH  - Peptides
MH  - *Sodium-Glucose Transporter 2 Inhibitors/adverse effects
OTO - NOTNLM
OT  - All-cause mortality
OT  - Dipeptidyl peptide-4 inhibitors
OT  - Major adverse cardiovascular events
OT  - Sodium-glucose cotransporter-2 inhibitors
OT  - Type 2 diabetes mellitus
EDAT- 2020/09/06 06:00
MHDA- 2021/10/16 06:00
CRDT- 2020/09/05 12:19
PHST- 2020/07/27 00:00 [received]
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2020/09/05 12:19 [entrez]
AID - S1751-9918(20)30248-5 [pii]
AID - 10.1016/j.pcd.2020.08.012 [doi]
PST - ppublish
SO  - Prim Care Diabetes. 2021 Apr;15(2):227-233. doi: 10.1016/j.pcd.2020.08.012. Epub 
      2020 Sep 1.